- Scheme Category:
- Equity Scheme >
- Sectoral/Thematic Funds
NAV: ₹ ↓ -0.94%
NAV chart
SMA (Simple Moving Average)
- 50 SMA
- 100 SMA
- 200 SMA
- 400 SMA
Returns
CAGR returns till date
CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option and its peers as on 27 March, 2026| Name | YTD | 1D | 1W | 1M | 3M | 1Y | 3Y | 5Y | 7Y | 10Y |
|---|---|---|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option | -2.47% | -0.94% | -0.27% | -3.72% | -2.45% | 3.77% | 23.7% | 16.33% | 19.77% | 15.06% |
| SBI CONSUMPTION OPPORTUNITIES FUND - DIRECT PLAN - GROWTH | -12.96% | -2.07% | -1.09% | -8.7% | -13.09% | -8.96% | 11.62% | 15.36% | 13.63% | 14.88% |
| SBI ESG Exclusionary Strategy Fund - Direct Plan -Growth | -12.61% | -2.24% | -0.95% | -10.59% | -12.07% | -3.46% | 12.26% | 10.75% | 11.9% | 12.42% |
| SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH | 0.78% | 1.53% | 0.74% | -1.67% | 0.39% | 2.66% | 27.04% | 18.94% | 21.36% | 13.22% |
| SBI INFRASTRUCTURE FUND - DIRECT PLAN - GROWTH | -10.47% | -2.07% | -2.16% | -9.51% | -9.75% | -2.8% | 18.56% | 19.21% | 17.71% | 16.19% |
| SBI PSU Fund - DIRECT PLAN - GROWTH | -2.2% | -1.52% | -2.43% | -10.51% | -0.18% | 11.92% | 32.82% | 27.41% | 19.26% | 15.9% |
Discrete returns (yearly)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | -9.42% | 8.09% | 4.71% | 2.97% | 68.53% | 23.84% | -9.16% | 41.33% | 35.46% | -2.94% |
Discrete returns (monthly)
| Month | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | 1.43% | 3% | 2.66% | -1.41% | -2.52% | 2.24% | 0.9% | -1.24% | -4.66% | 5.31% |
Returns from spefic dates
| Description | CAGR returns from 18 Oct 2021 (Nifty 50 2021 high) | CAGR returns from 26 Sep 2024 (Nifty 50 2024 high) |
|---|---|---|
| Returns | 12.14% | -2.4% |
Portfolio
Asset allocation
| Equity | Debt | Realestate | Commodities | Cash & Equivalents |
|---|---|---|---|---|
| 99.67% | 0.00% (Arbitrage: 0.00%) | 0.00% | 0.00% | 0.33% |
Equity
| Name | Symbol / ISIN | Sector | Weight % |
|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA (INE044A01036) | Pharmaceuticals & Biotechnology | 12.67% |
| Divi's Laboratories Limited | DIVISLAB (INE361B01024) | Pharmaceuticals & Biotechnology | 8.07% |
| Lupin Limited | LUPIN (INE326A01037) | Pharmaceuticals & Biotechnology | 7.26% |
| Cipla Limited | CIPLA (INE059A01026) | Pharmaceuticals & Biotechnology | 6.29% |
| Apollo Hospitals Enterprise Limited | APOLLOHOSP (INE437A01024) | Healthcare Services | 5.97% |
| Dr. Reddy's Laboratories Limited | DRREDDY (INE089A01031) | Pharmaceuticals & Biotechnology | 5.62% |
| Vijaya Diagnostic Centre Limited | VIJAYA (INE043W01024) | Healthcare Services | 3.42% |
| MedPlus Health Services Limited | MEDPLUS (INE804L01022) | Retailing | 3.32% |
| Gland Pharma Limited | GLAND (INE068V01023) | Pharmaceuticals & Biotechnology | 3.05% |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO (INE159A01016) | Pharmaceuticals & Biotechnology | 2.87% |
| Ajanta Pharma Limited | AJANTPHARM (INE031B01049) | Pharmaceuticals & Biotechnology | 2.83% |
| Sai Life Sciences Limited | SAILIFE (INE570L01029) | Pharmaceuticals & Biotechnology | 2.81% |
| Thyrocare Technologies Limited | THYROCARE (INE594H01019) | Healthcare Services | 2.59% |
| Abbott India Limited | ABBOTINDIA (INE358A01014) | Pharmaceuticals & Biotechnology | 2.39% |
| Aurobindo Pharma Limited | AUROPHARMA (INE406A01037) | Pharmaceuticals & Biotechnology | 2.32% |
| Dr. Lal Path Labs Limited | LALPATHLAB (INE600L01024) | Healthcare Services | 2.29% |
| Mankind Pharma Limited | MANKIND (INE634S01028) | Pharmaceuticals & Biotechnology | 2.16% |
| Alkem Laboratories Limited | ALKEM (INE540L01014) | Pharmaceuticals & Biotechnology | 2.14% |
| Biocon Limited | BIOCON (INE376G01013) | Pharmaceuticals & Biotechnology | 2.10% |
| JB Chemicals & Pharmaceuticals Limited | JBCHEPHARM (INE572A01036) | Pharmaceuticals & Biotechnology | 2.01% |
| Pfizer Limited | PFIZER (INE182A01018) | Pharmaceuticals & Biotechnology | 1.99% |
| Narayana Hrudayalaya Limited | NH (INE410P01011) | Healthcare Services | 1.95% |
| IPCA Laboratories Limited | IPCALAB (INE571A01038) | Pharmaceuticals & Biotechnology | 1.50% |
| Suraksha Diagnostic Limited | SURAKSHA (INE877V01027) | Healthcare Services | 1.48% |
| Fortis Healthcare Limited | FORTIS (INE061F01013) | Healthcare Services | 1.35% |
| Sanofi India Limited | SANOFI (INE058A01010) | Pharmaceuticals & Biotechnology | 1.32% |
| Sanofi Consumer Healthcare India Limited | SANOFICONR (INE0UOS01011) | Pharmaceuticals & Biotechnology | 1.24% |
| Max Healthcare Institute Limited | MAXHEALTH (INE027H01010) | Healthcare Services | 1.23% |
| Syngene International Limited | SYNGENE (INE398R01022) | Healthcare Services | 1.00% |
| Anthem Biosciences Limited | ANTHEM (INE0CZ201020) | Pharmaceuticals & Biotechnology | 0.90% |
| Akums Drugs and Pharmaceuticals Limited | AKUMS (INE09XN01023) | Pharmaceuticals & Biotechnology | 0.84% |
| Emcure Pharmaceuticals Limited | EMCURE (INE168P01015) | Pharmaceuticals & Biotechnology | 0.74% |
| AstraZeneca Pharma India Limited | ASTRAZEN (INE203A01020) | Pharmaceuticals & Biotechnology | 0.72% |
| Indoco Remedies Limited | INDOCO (INE873D01024) | Pharmaceuticals & Biotechnology | 0.61% |
| Orchid Pharma Limited | ORCHPHARMA (INE191A01027) | Pharmaceuticals & Biotechnology | 0.43% |
| Concord Biotech Limited | CONCORDBIO (INE338H01029) | Pharmaceuticals & Biotechnology | 0.19% |
Portfolio data is as on date 31 October, 2025
NAV history
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - 30 days NAV (Net asset value) history
| Date | NAV | % change |
|---|---|---|
| 27 March, 2026 | 555.4694 | -0.94% |
| 25 March, 2026 | 560.7225 | 1.58% |
| 24 March, 2026 | 552.0262 | 1.16% |
| 23 March, 2026 | 545.6965 | -2.02% |
| 20 March, 2026 | 556.9533 | 1.12% |
| 19 March, 2026 | 550.7881 | -2.25% |
| 18 March, 2026 | 563.4925 | 0.54% |
| 17 March, 2026 | 560.4429 | 0.33% |
| 16 March, 2026 | 558.6226 | -0.89% |
| 13 March, 2026 | 563.6405 | -1.79% |
| 12 March, 2026 | 573.9037 | -0.4% |
| 11 March, 2026 | 576.2219 | 0.16% |
| 10 March, 2026 | 575.3163 | 0.85% |
| 9 March, 2026 | 570.4757 | -0.28% |
| 6 March, 2026 | 572.0800 | -0.24% |
| 5 March, 2026 | 573.4843 | 1.19% |
| 4 March, 2026 | 566.7355 | -1.34% |
| 2 March, 2026 | 574.4547 | -0.43% |
| 27 February, 2026 | 576.9248 | -0.89% |
| 26 February, 2026 | 582.0874 | 0.79% |
| 25 February, 2026 | 577.5420 | 1.36% |
| 24 February, 2026 | 569.7749 | -0.24% |
| 23 February, 2026 | 571.1316 | 0.82% |
| 20 February, 2026 | 566.4993 | -0.03% |
| 19 February, 2026 | 566.6474 | -0.54% |
| 18 February, 2026 | 569.7016 | 0.01% |
| 17 February, 2026 | 569.6540 | 0.5% |
| 16 February, 2026 | 566.7947 | 0.74% |
| 13 February, 2026 | 562.6333 | -0.79% |
| 12 February, 2026 | 567.1247 |
FAQ (Frequently asked questions)
What is latest/current NAV/price of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The latest NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 555.4694 as on 27 March, 2026.What are YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are -2.47% as on 27 March, 2026.What are 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 3.77% as on 27 March, 2026.What are 3 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 3 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 23.7% as on 27 March, 2026.What are 5 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 5 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 16.33% as on 27 March, 2026.What are 10 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 10 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 16.33% as on 27 March, 2026.